Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Working Capital (2020 - 2021)

Gain Therapeutics (GANX) has 2 years of Change in Working Capital data on record, last reported at $1.4 million in Q4 2021.

  • For Q4 2021, Change in Working Capital rose 617.86% year-over-year to $1.4 million; the TTM value through Dec 2021 reached $329784.0, up 233.94%, while the annual FY2021 figure was $329784.0, 233.94% up from the prior year.
  • Change in Working Capital reached $1.4 million in Q4 2021 per GANX's latest filing, up from -$1.7 million in the prior quarter.
  • Across five years, Change in Working Capital topped out at $1.4 million in Q4 2021 and bottomed at -$1.7 million in Q3 2021.